Medicenna Therapeutics (TSE:MDNA) has released an update.
Medicenna Therapeutics has reported promising results from their ABILITY-1 study of MDNA11, an immunotherapy for advanced solid tumors, at the AACR 2024 Annual Meeting. The drug showed a 29% response rate and 50% clinical benefit rate in patients who had not responded to checkpoint inhibitors, with a notable 100% reduction in target lesions for some patients. MDNA11 demonstrated an acceptable safety profile with no severe adverse events, bolstering its potential as a best-in-class treatment option.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
